Sarcoma

Research Article

Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor

Table 1

Relative cytotoxic potency of doxorubicin-loaded vehicles: ratio of (IC50)⁻¹ between vehicles summarized by geometric mean (95% confidence interval).


Osteosarcoma cell line	Untargeted HPLNs	Targeted HPLNs	Targeted HPLNs	Free Dox
	over	over	over	over
	conventional liposomes	untargeted HPLNs	conventional liposomes	targeted HPLNs

KHOS240s	5.4 (3.7–8.0)	2.3 (1.5–3.3)	12.2 (8.3–18.0)	3.1 (2.1–4.6)
HOS	7.0 (4.8–10.1)	1.7 (1.1–2.4)	11.6 (8.0–16.8)	3.1 (2.1–4.5)
MNNG-HOS	11.4 (5.4–23.9)	2.0 (0.95–4.2)	22.8 (10.8–47.8)	3.6 (1.7–7.5)

Summary of all 3 lines	5.9 (4.6–7.6)	2.0 (1.6–2.5)	11.8 (9.2–15.2)	3.2 (2.6–4.1)

Tukey HSD 95% confidence intervals for multiple comparisons in each cell line.
Based on linear mixed effects model for log IC50 as a function of cell line and vehicle.
Indicated potency ratio is 2.0-fold greater (95% CI: 1.4–2.8) in MNNG-HOS cell line, consistent with significant cell line by vehicle interaction (P = 0.015).